Janet Hammond, M.D., Ph.D., has been appointed vice president of Translational Medicine – Virology in Pharmaceutical Research and Early Development (pRED) at Roche. Dr. Hammond will report to Jacques Banchereau, Ph.D., Discovery and Translational Area (DTA) head for Inflammation and Virology, and chief scientific officer at Nutley. She will be responsible for driving strategy and implementation of early clinical development for the Virology DTA.

Dr. Hammond has 13 years of experience in the pharmaceutical industry. Prior to joining the company, Dr. Hammond served as chief medical officer and senior vice president of Global Medical Affairs at Valeant Pharmaceuticals, where she was responsible for medical affairs and worldwide pharmacovigilence activities. As chair of the Global Safety Board, she was also responsible for ensuring patient, clinical trial and product safety. Other positions include serving as group director, Global Clinical Research, Virology and Infections Diseases at Bristol-Myers Squibb, and head of Clinical Drug Discovery Virology at GlaxoSmithKline.

“Janet’s background and experience will be a great addition to our efforts to drive Translational Medicine as well as Virology within Roche as we continue our quest to find new and more effective approaches to drug development, ultimately providing better options for patients,” said Dr. Banchereau.